Key Highlights
- Loss per share of USD 0.28 was narrower than the USD 0.31 estimate, and Revenue of USD 519,000 missed estimates.
- Net loss was USD 26.8 million against USD 22.2 million, and Research and Development expense rose to USD 21.3 million.
- Selling, general and administrative expense rose USD 3.1 million to USD 8.9 million, and operating loss was USD 29.8 million.
- Cash and restricted cash were USD 236.3 million, and USD 308.6 million of share proceeds were received in nine months.
Anteris Technologies Global Corp. (NASDAQ:AVR), a structural heart technology company, reported a third quarter 2026 loss of USD 0.28 per share against an estimated loss of USD 0.31 and USD 0.62 a year earlier. Revenue of USD 519,000 was below the USD 2.75 million estimate. Net loss was USD 26.83 million against USD 22.21 million.
For the nine months, net loss was USD 78.50 million against USD 65.20 million, and loss per share was USD 0.85 against USD 1.80.
Operating Expenses
Research and development expense was USD 21.33 million against USD 16.81 million, and selling, general and administrative expense was USD 8.90 million against USD 5.76 million. Operating loss was USD 29.84 million against USD 22.27 million. Other non-operating income, net was USD 2.60 million against USD 147,000, and interest and amortization of Debt discount was USD 17,000 against USD 15,000. The income tax benefit was USD 272,000 for the quarter against none a year earlier, and nine-month income tax expense was USD 220,000.
For the nine months, research and development expense was USD 62.16 million against USD 49.61 million, and selling, general and administrative expense was USD 24.24 million against USD 16.45 million, an increase of USD 7.8 million, or 47%. Operating loss for the nine months was USD 84.85 million against USD 64.93 million.
Cash and Financing
Cash, cash equivalents and restricted cash were USD 236.3 million at September 30, 2026, including USD 3.6 million classified as a non-current asset. The filing states the company received USD 308.6 million of proceeds from issuing common stock during the nine months, net of Underwriting fees, partly offset by USD 8.8 million of share issuance costs, against USD 0.6 million of proceeds in the prior year period.
The accumulated Deficit was USD 449.5 million against USD 370.5 million at December 31, 2025. The filing states no shares of common stock had been sold under the at-the-market program as of September 30, 2026.
Legal Disclosure and Items to Follow
The filing states the company is party to various claims and lawsuits in the ordinary course of operations and is not party to any material legal proceedings. The weighted average share count rose substantially from a year earlier, which affects per share comparisons. Cost of products sold was USD 126,000 for the quarter against USD 123,000, and net foreign exchange gains and losses and an income tax benefit of USD 272,000 also affected net loss. The items to follow are research and development spending, selling and administrative costs, product revenue and the cash balance.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...